GLUE – monte rosa therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story [Yahoo! Finance]
Monte Rosa Therapeutics (GLUE) was downgraded by Wall Street Zen from
Monte Rosa Therapeutics (GLUE) had its price target lowered by Guggenheim from $34.00 to $30.00. They now have a "buy" rating on the stock.
Monte Rosa Therapeutics (GLUE) had its price target lowered by Wells Fargo & Company from $30.00 to $29.00. They now have an "overweight" rating on the stock.
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates [Yahoo! Finance]
Form SCHEDULE 13D/A Monte Rosa Therapeutics, Filed by: New Enterprise Associates 17, L.P.
Form S-8 Monte Rosa Therapeutics,
Form 10-K Monte Rosa Therapeutics, For: Dec 31
Form 8-K Monte Rosa Therapeutics, For: Mar 17
Form 4 Monte Rosa Therapeutics, For: Mar 04 Filed by: Dunn Edmund
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.